Maali A, Noei A, Feghhi-Najafabadi S, Sharifzadeh Z
Iran Biomed J. 2025; 28(5 & 6):221-34.
PMID: 39891450
PMC: 11829154.
DOI: 10.61186/ibj.4444.
Vera-Cruz S, Jornet Culubret M, Konetzki V, Alb M, Friedel S, Hudecek M
Cancers (Basel). 2024; 16(22).
PMID: 39594822
PMC: 11592760.
DOI: 10.3390/cancers16223867.
Becher B, Derfuss T, Liblau R
Nat Rev Drug Discov. 2024; 23(11):862-879.
PMID: 39261632
DOI: 10.1038/s41573-024-01026-y.
Pan D, Richter J
Curr Hematol Malig Rep. 2024; 19(6):237-245.
PMID: 39145912
DOI: 10.1007/s11899-024-00740-z.
van Meerten T, Kuruvilla J, Song K, Thieblemont C, Minnema M, Forcade E
Am J Cancer Res. 2024; 14(6):2905-2920.
PMID: 39005691
PMC: 11236767.
DOI: 10.62347/LLXR8002.
Mechanisms and management of CAR T toxicity.
Ferreri C, Bhutani M
Front Oncol. 2024; 14:1396490.
PMID: 38835382
PMC: 11148294.
DOI: 10.3389/fonc.2024.1396490.
Current understanding and management of CAR T cell-associated toxicities.
Brudno J, Kochenderfer J
Nat Rev Clin Oncol. 2024; 21(7):501-521.
PMID: 38769449
PMC: 11529341.
DOI: 10.1038/s41571-024-00903-0.
Immunopathology of and potential therapeutics for secondary hemophagocytic lymphohistiocytosis/macrophage activation syndrome: a translational perspective.
Nguyen T, Kim Y, Jeong G, Jin M
Exp Mol Med. 2024; 56(3):559-569.
PMID: 38448692
PMC: 10984945.
DOI: 10.1038/s12276-024-01182-6.
Managing side effects: guidance for use of immunotherapies in multiple myeloma.
Liang E, Sidana S
Hematology Am Soc Hematol Educ Program. 2023; 2023(1):348-356.
PMID: 38066898
PMC: 10727020.
DOI: 10.1182/hematology.2023000435.
CAR-T cell therapy: Where are we now, and where are we heading?.
Wang J, Wang L
Blood Sci. 2023; 5(4):237-248.
PMID: 37941917
PMC: 10629745.
DOI: 10.1097/BS9.0000000000000173.
Teclistamab for Multiple Myeloma: Clinical Insights and Practical Considerations for a First-in-Class Bispecific Antibody.
Pan D, Richter J
Cancer Manag Res. 2023; 15:741-751.
PMID: 37497430
PMC: 10368105.
DOI: 10.2147/CMAR.S372237.
Strategies for Reducing Toxicity and Enhancing Efficacy of Chimeric Antigen Receptor T Cell Therapy in Hematological Malignancies.
Wang H, Tang L, Kong Y, Liu W, Zhu X, You Y
Int J Mol Sci. 2023; 24(11).
PMID: 37298069
PMC: 10252534.
DOI: 10.3390/ijms24119115.
How I treat refractory CRS and ICANS after CAR T-cell therapy.
Jain M, Smith M, Shah N
Blood. 2023; 141(20):2430-2442.
PMID: 36989488
PMC: 10329191.
DOI: 10.1182/blood.2022017414.
CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances.
Maalej K, Merhi M, Inchakalody V, Mestiri S, Alam M, Maccalli C
Mol Cancer. 2023; 22(1):20.
PMID: 36717905
PMC: 9885707.
DOI: 10.1186/s12943-023-01723-z.
Cardiotoxicity of T-Cell Antineoplastic Therapies: Primer.
Ganatra S, Dani S, Yang E, Zaha V, Nohria A
JACC CardioOncol. 2023; 4(5):616-623.
PMID: 36636447
PMC: 9830211.
DOI: 10.1016/j.jaccao.2022.07.014.
Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response.
Wang D, Wu X, Sun Y
Signal Transduct Target Ther. 2022; 7(1):331.
PMID: 36123348
PMC: 9485144.
DOI: 10.1038/s41392-022-01136-2.
The use of ICU resources in CAR-T cell recipients: a hospital-wide study.
Valade S, Darmon M, Zafrani L, Mariotte E, Lemiale V, Bredin S
Ann Intensive Care. 2022; 12(1):75.
PMID: 35976532
PMC: 9385897.
DOI: 10.1186/s13613-022-01036-2.
Cardiotoxicity of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Pathophysiology, Clinical Implications, and Echocardiographic Assessment.
Nenna A, Carpenito M, Chello C, Nappi P, Annibali O, Vincenzi B
Int J Mol Sci. 2022; 23(15).
PMID: 35897819
PMC: 9368621.
DOI: 10.3390/ijms23158242.
Interleukin Inhibitors in Cytokine Release Syndrome and Neurotoxicity Secondary to CAR-T Therapy.
Ferreros P, Trapero I
Diseases. 2022; 10(3).
PMID: 35892735
PMC: 9326641.
DOI: 10.3390/diseases10030041.
Cardiovascular Toxicities with Chimeric Antigen Receptor T-cell Therapy.
Gill J
Curr Cardiol Rev. 2022; 19(1):e230622206353.
PMID: 35747980
PMC: 10201875.
DOI: 10.2174/1573403X18666220623152350.
